Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab-containing regimens for diffuse large B-cell lymphoma unfit for full-dose R-CHOP
2019-000842-36Phase 2Unknown
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of polatuzumab vedotin, rituximab, gemcitabine, prednisolone, doxorubicin and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoint: 12-month progression-free survival rate. Status: unknown.
02
Drugs
polatuzumab vedotinrituximabgemcitabineprednisolonedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2019-000842-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000842-36.